Alert Data News | Business | Companies | UK | Chemicals, Pharmaceuticals, Biotechnology

Team Consulting Limited

Fri, 10 Feb 2012 09:39:23 +0000

Opening respiratory physics laboratory - creating jobs - manager appointed
Team Consulting has appointed a new respiratory physics laboratory in Ickleton, Cambridgeshire after 2011 proved to be its most successful year financially. The company plans to double in size within five years and will take on further office and laboratory space and more staff. Mark Shepherd has been appointed manager of the new laboratory.

Samuel Grant,Ltd

Thu, 09 Feb 2012 10:14:23 +0000

Centerpac acquired out of Administration - Turnover £18.2m - 80 Employees
Samuel Grant, supplier of packaging materials and eqiupment, have acquired Centerpac, a packaging supplies company, out of administration saving 12 jobs. Samuel Grant Group is the largest privately owned packaging distributor in the North employing 80 staff.

TOBY CHURCHILL LIMITED

Thu, 09 Feb 2012 09:02:16 +0000

Company Growth - Expansion into US
Cambridgeshire text-to-speech device company Toby Churchill is to open a US office in Denver, Colorado, in July. The US sales division will be a branch of the UK company and will include sales and marketing, customer and technical support, servicing and repairs. Toby Churchill is the company founder.

Smith & Nephew PLC

Wed, 08 Feb 2012 11:10:12 +0000

Revenue up 3% - Profit down 1% - Workforce reduced by 7%
Hull based Smith & Nephew, Europes biggest artificial knee and hip maker, has recorded a 1% fall in profits for the last three months in 2011 to £176m. Group revenue rose 3% for the same period to £698m. The company is to cut costs by £95m and will be reducing its workforce by 7%. Olivier Bohuon is Chief Executive of Smith & Nephew Plc.

Smith & Nephew PLC

Tue, 07 Feb 2012 02:37:00 +0000

£95m costs to be cut - 770 worldwide Jobs Lost - Profits down to £537m
Smith & Nephew, which employs 11,000 people worldwide including 1,200 in the UK, is to save £95m in costs over the next two years by cutting around 770 administrative jobs.

Xceleron Limited (In Administration)

Mon, 06 Feb 2012 15:47:50 +0000

Xceleron Announces New Investment
Xceleron Announces New Investment and Move to Purpose-Built Laboratories in U.S.

Xceleron Limited (In Administration)

Mon, 06 Feb 2012 15:47:50 +0000

Xceleron Lands $2.4M From Albion Ventures and Solon Ventures
Xceleron, a leader in accelerating drug development using ultra-sensitive bioanalytical analyses, today announced that existing investors Albion Ventures and Solon Ventures have invested $2.4MM to locate all of the company's business in its custom-built facility in Germantown, MD which is expected to be fully operational by 31st March 2012.

AstraZeneca PLC

Mon, 06 Feb 2012 09:30:46 +0000

7,300 job losses - 2% fall in revenues - competitive pressures
AstraZeneca is reducing headcount by 7,300 across its operations after revenue fell 2% to £22.2bn. Revenue in Western Europe fell 11% due to increased competition from generic drugs. It is not known which sites will be affected by the job cuts. The restructuring is expected to reduce costs and increase flexibility in functional areas.

AstraZeneca PLC

Mon, 06 Feb 2012 08:00:05 +0000

Revenue down 2% - Profit down 4% - 61700 Employees
AstraZeneca reorted revenue for the full year was down 2% at constant exchange rates at $33,591 million. Strong double-digit sales growth for Crestor, Seroquel XR and Symbicort; Emerging Markets revenue increased by 10%. Revenue performance reflects the loss of nearly $2 billion of revenue from generic competition, as well as a further $1 billion lost to the impact of government price interventions. David Brennan is Chief Executive Officer

Byotrol Plc

Fri, 03 Feb 2012 15:00:11 +0000

New product launched with partner - Contract extended worth £300,000
Byotrol plc, the developer of anti microbial hygiene technologies, and partner Rentokil Initial Plc, have formally launched the UltraProtect range, powered by Byotrol, under a contract announced in July 2011. UltraProtect is a range of hand and surface sanitising products for commercial and public use, featuring a gel hand sanitiser, a foam hand sanitiser, and handy packs of hand and surface wipes. In addition, Byotrol has agreed terms for a six month extension of the Joint Development Agreement ('JDA') with their Fortune 150 partner company, for which Byotrol Consumer Products Limited will receive $300,000. Gary Millar is the Chief Executive of Byotrol Plc.